This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Novo Nordisk A/s. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: The Innovations of Carl Richard Torstenson
Introduction
Carl Richard Torstenson is a notable inventor based in Limhamm, Denmark. He has made significant contributions to the field of medicine, particularly in the treatment of non-alcoholic steatohepatitis. His work has garnered attention for its potential impact on healthcare.
Latest Patents
Torstenson holds a patent for the use of semaglutide, a GLP-1 receptor agonist, in medical therapy. This invention is directed towards the treatment of non-alcoholic steatohepatitis, showcasing his commitment to advancing medical science. He has 1 patent to his name, reflecting his innovative approach to addressing health issues.
Career Highlights
Torstenson is associated with Novo Nordisk A/S, a leading global healthcare company. His role at the company has allowed him to work on groundbreaking therapies that aim to improve patient outcomes. His expertise in the field has positioned him as a valuable asset in the medical research community.
Collaborations
Throughout his career, Torstenson has collaborated with esteemed colleagues such as Morten Hansen and Martin Linder. These partnerships have fostered an environment of innovation and have contributed to the development of effective medical solutions.
Conclusion
Carl Richard Torstenson's contributions to the field of medicine through his patent on semaglutide highlight his dedication to improving healthcare. His work at Novo Nordisk A/S and collaborations with other professionals further emphasize his role as an influential inventor in the medical field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile